Drugs / RSV/hMPV\_V
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07628049 | Jun 2026 → Apr 2029 expected | Mononegavirales infectious disease | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV/hMPV\_V | “RSV/hMPV\_V low dose vaccine administered intramuscularly.” NCT07628049 ↗ |
| Modality | Vaccine | “RSV/hMPV\_V low dose vaccine administered intramuscularly.” NCT07628049 ↗ |
| Route | Intramuscular | “RSV/hMPV\_V low dose vaccine administered intramuscularly.” NCT07628049 ↗ |